A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib. by Vanessa Augis, Kelly Airiau, Marina Josselin, Béatrice Turcq, François-Xavier Mahon, Francis Belloc

Get full text

Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials by Min Tang, Jasmine Foo, Mithat Gönen, Joëlle Guilhot, François-Xavier Mahon, Franziska Michor

Get full text

PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE by Andreas Hochhaus, Susanne Saussele, Francois-Xavier Mahon, Virginia Pilipovic, Yifan Zhang, Peter Schuld, Tim H Brümmendorf

Get full text

A genome‐scale CRISPR knock‐out screen in chronic myeloid leukemia identifies novel drug resistance mechanisms along with intrinsic apoptosis and MAPK signaling by Matthieu Lewis, Valérie Prouzet‐Mauléon, Florence Lichou, Elodie Richard, Richard Iggo, Béatrice Turcq, François‐Xavier Mahon

Get full text

Dasatinib-Loaded Erythrocytes Trigger Apoptosis in Untreated Chronic Myelogenous Leukemic Cells: A Cellular Reservoir Participating in Dasatinib Efficiency by Kelly Airiau, Béatrice Turcq, Stéphane Bouchet, Elodie Laharanne, Jean-Philippe Vial, Gabriel Etienne, François-Xavier Mahon, Francis Belloc

Get full text

Novel analytical methods to interpret large sequencing data from small sample sizes by Florence Lichou, Sébastien Orazio, Stéphanie Dulucq, Gabriel Etienne, Michel Longy, Christophe Hubert, Alexis Groppi, Alain Monnereau, François-Xavier Mahon, Béatrice Turcq

Get full text

The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cells. by Gwendaline Guidicelli, Benjamin Chaigne-Delalande, Marie-Sarah Dilhuydy, Benoît Pinson, Walid Mahfouf, Jean-Max Pasquet, François-Xavier Mahon, Philippe Pourquier, Jean-François Moreau, Patrick Legembre

Get full text

Variable behavior of iPSCs derived from CML patients for response to TKI and hematopoietic differentiation. by Aurélie Bedel, Jean-Max Pasquet, Eric Lippert, Miguel Taillepierre, Valérie Lagarde, Sandrine Dabernat, Pierre Dubus, Lucie Charaf, François Beliveau, Hubert de Verneuil, Emmanuel Richard, François-Xavier Mahon, François Moreau-Gaudry

Get full text

Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy by Eric Lippert, Gabriel Etienne, Marie-Joelle Mozziconacci, Sophy Laibe, Carine Gervais, Stéphane Girault, Nathalie Gachard, Isabelle Tigaud, Nicole Dastugue, François Huguet, Marie-Pierre Fort, Laurence Legros, Virginie Eclache, Francois-Xavier Mahon

Get full text

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy by Gabriel Etienne, Stéphanie Dulucq, Franck-Emmanuel Nicolini, Stéphane Morisset, Marie-Pierre Fort, Anna Schmitt, Madeleine Etienne, Sandrine Hayette, Eric Lippert, Caroline Bureau, Isabelle Tigaud, Didier Adiko, Gérald Marit, Josy Reiffers, François-Xavier Mahon

Get full text

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation by Franck E. Nicolini, Sandrine Hayette, Selim Corm, Emmanuel Bachy, Dominique Bories, Michel Tulliez, François Guilhot, Laurence Legros, Frédéric Maloisel, Jean-Jacques Kiladjian, François-Xavier Mahon, Quoc-Hung Lê, Mauricette Michallet, Catherine Roche-Lestienne, Claude Preudhomme

Get full text

MiR-10a and HOXB4 are overexpressed in atypical myeloproliferative neoplasms by Pierre-Yves Dumas, Olivier Mansier, Valerie Prouzet-Mauleon, Junji Koya, Arnaud Villacreces, Philippe Brunet de la Grange, Damien Luque Paz, Audrey Bidet, Jean-Max Pasquet, Vincent Praloran, Franck Salin, Mineo Kurokawa, François-Xavier Mahon, Bruno Cardinaud, Eric Lippert

Get full text

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors by Gabriel Etienne, Stéphanie Dulucq, Françoise Huguet, Anna Schmitt, Axelle Lascaux, Sandrine Hayette, Marie‐Pierre Fort, Pierre Sujobert, Fontanet Bijou, Stéphane Morisset, Suzanne Tavitian, Audrey Bidet, Beatrice Turcq, Fanny Robbesyn, Claudine Chollet, Francis Belloc, Françoise Durrieu, François‐Xavier Mahon, Franck E. Nicolini

Get full text

Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission by Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Frédéric Bauduer, Kaddour Chabane, Patrice Chevallier, Pascale Cony-Makhoul, Pascale Flandrin-Gresta, Caroline Le Jeune, Yannick Le Bris, Laurence Legros, Hervé Maisonneuve, Lydia Roy, Francois-Xavier Mahon, Ivan Sloma, Delphine Rea, Franck Emmanuel Nicolini

Get full text

Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells by Anne Trinh, Raeeka Khamari, Quentin Fovez, François-Xavier Mahon, Béatrice Turcq, Didier Bouscary, Patrice Maboudou, Marie Joncquel, Valérie Coiteux, Nicolas Germain, William Laine, Salim Dekiouk, Sandrine Jean-Pierre, Veronique Maguer-Satta, Bart Ghesquiere, Thierry Idziorek, Bruno Quesnel, Jerome Kluza, Philippe Marchetti

Get full text

Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients by Gaëlle Fossard, Emilie Blond, Marie Balsat, Stéphane Morisset, Stéphane Giraudier, Martine Escoffre-Barbe, Hélène Labussière-Wallet, Maël Heiblig, Arthur Bert, Madeleine Etienne, Jocelyne Drai, Mohamad Sobh, Isabelle Redonnet-Vernhet, Jean-Christophe Lega, François-Xavier Mahon, Gabriel Etienne, Franck Emmanuel Nicolini

Get full text

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission by Pierre‐Yves Dumas, Emilie Bérard, Claire Bréal, Stéphanie Dulucq, Delphine Réa, Franck Nicolini, Edouard Forcade, Melody Dufossée, Jean‐Max Pasquet, Béatrice Turcq, Audrey Bidet, Noel Milpied, Julie Déchanet‐Merville, Xavier Lafarge, Gabriel Etienne, François‐Xavier Mahon, French Intergroup in Chronic Myeloid Leukemia

Get full text

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study by Delphine Rea, Guylaine Henry, Zena Khaznadar, Gabriel Etienne, François Guilhot, Franck Nicolini, Joelle Guilhot, Philippe Rousselot, Françoise Huguet, Laurence Legros, Martine Gardembas, Viviane Dubruille, Agnès Guerci-Bresler, Aude Charbonnier, Frédéric Maloisel, Jean-Christophe Ianotto, Bruno Villemagne, François-Xavier Mahon, Hélène Moins-Teisserenc, Nicolas Dulphy, Antoine Toubert

Get full text

Relevance of treatment‐free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors by Gabriel Etienne, Carole Faberes, Fréderic Bauduer, Didier Adiko, François Lifermann, Corinne Dagada, Caroline Lenoir, Anna Schmitt, Emilie Klein, Marie‐Pierre Fort, Fontanet Bijou, Beatrice Turcq, Fanny Robbesyn, Françoise Durrieu, Laura Versmée, Samia Madene, Marius Moldovan, Sandrine Katsahian, Anais Charles‐Nelson, Axelle Lascaux, François‐Xavier Mahon, Stéphanie Dulucq

Get full text

S155: PROGNOSTIC FACTORS FOR 3-YEAR MAJOR MOLECULAR RESPONSE MAINTENANCE IN CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE EUROPEAN STOP KINASE INHIBITORS (EURO-SKI) TRIAL by Markus Pfirrmann, Francois-Xavier Mahon, Stéphanie Dulucq, Andreas Hochhaus, Panayiotis Panayiotidis, Antonio Almeida, Jiri Mayer, Henrik Hjorth-Hansen, Jeroen J. W. M. Janssen, Satu Mustjoki, Joaquín Martinez-Lopez, Hanne Vestergaard, Hans Ehrencrona, Veli Kairisto, Kateřina Machová Poláková, Franck Emmanuel Nicolini, Wolf-Karsten Hofmann, Joëlle Guilhot, Susanne Saussele, Johan Richter

Get full text